USA - NASDAQ:KRYS - US5011471027 - Common Stock
We assign a fundamental rating of 6 out of 10 to KRYS. KRYS was compared to 534 industry peers in the Biotechnology industry. While KRYS has a great health rating, its profitability is only average at the moment. A decent growth rate in combination with a cheap valuation! Better keep an eye on KRYS. This makes KRYS very considerable for value investing!
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.89% | ||
| ROE | 14.1% | ||
| ROIC | 12.87% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 42.26% | ||
| PM (TTM) | 40.85% | ||
| GM | 93.37% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 34.54 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.68 | ||
| Quick Ratio | 9.33 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 38.1 | ||
| Fwd PE | 23.93 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 29.25 | ||
| EV/EBITDA | 27.95 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:KRYS (10/24/2025, 10:55:37 AM)
187.44
+0.99 (+0.53%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 38.1 | ||
| Fwd PE | 23.93 | ||
| P/S | 15.1 | ||
| P/FCF | 29.25 | ||
| P/OCF | 27.76 | ||
| P/B | 5.21 | ||
| P/tB | 5.21 | ||
| EV/EBITDA | 27.95 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.89% | ||
| ROE | 14.1% | ||
| ROCE | 14.44% | ||
| ROIC | 12.87% | ||
| ROICexc | 36.62% | ||
| ROICexgc | 36.62% | ||
| OM | 42.26% | ||
| PM (TTM) | 40.85% | ||
| GM | 93.37% | ||
| FCFM | 51.63% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 195.35% | ||
| Cap/Sales | 2.77% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 124.54% | ||
| Profit Quality | 126.39% | ||
| Current Ratio | 9.68 | ||
| Quick Ratio | 9.33 | ||
| Altman-Z | 34.54 |
ChartMill assigns a fundamental rating of 6 / 10 to KRYS.
ChartMill assigns a valuation rating of 7 / 10 to KRYSTAL BIOTECH INC (KRYS). This can be considered as Undervalued.
KRYSTAL BIOTECH INC (KRYS) has a profitability rating of 6 / 10.
The financial health rating of KRYSTAL BIOTECH INC (KRYS) is 8 / 10.